- Home
- / Qubit Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Qubit Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and acquistions and subsidiaries.
Revenue
€76.7 K
FY, 2023
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|
| Revenue | 76.7K | ||
| General and administrative expense | 645.0K | 1.4M | 2.9M |
| Operating expense total | 1.6M | 4.3M | 9.9M |
| Depreciation and amortization | 96.1K | 293.0K | 487.6K |
| EBIT | (603.2K) | (1.6M) | (2.0M) |
| EBIT margin, % | -2653.2% | ||
| Interest income | 909.0 | 6.6K | |
| Interest expense | 14.2K | 43.0K | 40.2K |
| Pre tax profit | (619.6K) | (1.6M) | (2.1M) |
| Income tax expense | (244.7K) | (723.3K) | (1.9M) |
| Net Income | (374.8K) | (884.1K) | (133.4K) |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |